Based on these findings, one can hypothesize that the targeting of Tpl2 could have beneficial effects in the context of obesity by reducing the production of inflammatory cytokines by adipose tissue immune cells and by blocking their deleterious effects in adipocytes. The gene discussed is MAP3K8; the disease is obesity due to melanocortin 4 receptor deficiency.